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S3I-201 (NSC 74859) is a chemical probe inhibitor of Stat3 activity,
which was identified from the National Cancer Institute chemical
libraries by using structure-based virtual screening with a com-
puter model of the Stat3 SH2 domain bound to its Stat3 phospho-
tyrosine peptide derived from the x-ray crystal structure of the
Stat3 homodimer. S3I-201 inhibits Stat3Stat3 complex formation
and Stat3 DNA-binding and transcriptional activities. Furthermore,
S3I-201 inhibits growth and induces apoptosis preferentially in
tumor cells that contain persistently activated Stat3. Constitutively
dimerized and active Stat3C and Stat3 SH2 domain rescue tumor
cells from S3I-201-induced apoptosis. Finally, S3I-201 inhibits the
expression of the Stat3-regulated genes encoding cyclin D1, Bcl-xL,
and survivin and inhibits the growth of human breast tumors in vivo.
These findings strongly suggest that the antitumor activity of S3I-201
ismediated inpart through inhibitionof aberrant Stat3activationand
provide the proof-of-concept for the potential clinical use of Stat3
inhibitors such as S3I-201 in tumors harboring aberrant Stat3.
Proteins of the STAT (signal transducer and activator of tran-scription) family are activated in response to cytokines and
growth factors and promote proliferation, survival, and other
biological processes (1–3). STATs are activated by phosphorylation
of a critical tyrosine residue, which is mediated by growth factor
receptor tyrosine kinases, Janus kinases, or the Src family kinases.
Upon tyrosine phosphorylation, dimers of STATs formed between
two phosphorylated monomers translocate to the nucleus, bind to
specific DNA-response elements in the promoters of target genes,
and induce gene expression. Aberrant activity of one of the family
members, Stat3, contributes to carcinogenesis and tumor progres-
sion by up-regulating gene expression and promoting dysregulated
growth, survival, and angiogenesis and modulating immune re-
sponses (2–9).
As a critical step in STAT activation (10), the dimerization
between two STAT monomers presents an attractive target to
abolish Stat3 DNA-binding and transcriptional activity and to
inhibit Stat3 biological functions (11, 12). Stat3 dimerization relies
on the reciprocal binding of the SH2 domain of one monomer to
the Pro-pTyr-Leu-Lys-Thr-Lys sequence of the other Stat3 mono-
mer. To pursue the development of inhibitors of Stat3 signaling, key
structural information gleaned from the x-ray crystal structure of
the Stat3 homodimer (13) was used in the computational mod-
eling and automated docking of small molecules into the SH2
domain of a Stat3 monomer, relative to the bound native pTyr
peptide, to identify binders of the Stat3 SH2 domain, and poten-
tially disruptors of Stat3Stat3 dimers (14, 15).
Structure-based high-throughput virtual screening of the Na-
tional Cancer Institute (NCI) chemical libraries identified the
high-scoring compound NSC 74859 (resynthesized as a pure sample
and named S3I-201), which selectively inhibits Stat3 DNA-binding
activity in vitro with an IC50 value of 86 33 M. Furthermore,
S3I-201 induces growth inhibition and apoptosis of malignant cells
in part by constitutively inhibiting active Stat3 and induces human
breast tumor regression in xenograft models.
Results
Computational Modeling and Virtual Screening. Our computational
modeling and virtual screening study used the GLIDE (Grid-based
Ligand Docking from Energetics) software (16, 17) (available from
Schro¨dinger, Portland, OR) for the docking simulations and relied
on the x-ray crystal structure of the Stat3 homodimer bound to
DNA (13) determined at 2.25-Å resolution (1BG1 in the Protein
Data Bank). For the virtual screening, DNA was removed and only
one of the two monomers was used (see Fig. 1). To validate the
docking approach, the native pTyr (pY) peptide, APpYLKT, was
extracted from the crystal structure of one of the monomers and
docked to the other monomer, whereby GLIDE produced a
docking mode that closely resembled the x-ray crystal structure
(data not shown). Three-dimensional structures of compounds
from the NCI’s chemical libraries were downloaded from the NCI
Developmental Therapeutics Program web site (http://dtp.nci.nih.
gov/docs/3ddatabase/Structuralinformation/structuraldata.html)
and processed with LigPrep software (available from Schro¨dinger)
to produce 2,392 3D structures for the Diversity Set and 150,829 3D
structures for the Plated Set. Then GLIDE 2.7 SP (Standard
Precision mode) docked each chemical structure (for small mole-
cule) into the pTyr peptide-binding site within the SH2 domain of
the monomer to obtain the best docking mode and docking score.
The best score observed from the docking studies was 11.7
kcal/mol, relative to the native phosphopeptide sequence APpYLK
(scored as 11.9 kcal/mol). Typically, compounds receiving highly
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favorable scores (more negative values) have structural features
that include sulfonyl, carboxyl, and hydroxyl functional groups. The
current hit, S3I-201 (NSC 74859), contains all three groups.
Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding
Activity. The best-scoring compounds were selected for experimen-
tal analysis using an in vitro Stat3 DNA-binding assay and EMSA
analysis. See supporting information (SI) Results for more details.
Results for the confirmed hit, S3I-201, show differential inhibition
of DNA-binding activities of STATs. Fig. 2A Left shows potent
inhibition of Stat3 DNA-binding activity by S3I-201, with an
average IC50 value of 86 33 M. For selectivity against STAT
family members, nuclear extract preparations from EGF-
stimulated mouse fibroblasts overexpressing the human epidermal
growth factor receptor (EGFR) NIH 3T3/hEGFR, containing
activated Stat1, Stat3, and Stat5, were preincubated with or without
S3I-201 before incubation with the radiolabeled probes, as de-
scribed in Materials and Methods. EMSA analysis of the DNA-
binding activities shows Stat3Stat3 (upper), Stat1Stat3 (interme-
diate) and Stat1Stat1 (lower) bands of complexes with the hSIE
probe (Fig. 2ARight Upper) and Stat5Stat5 (upper) and Stat1Stat1
(lower) bands of complexes with the MGFe probe (Fig. 2A Right
Lower). S3I-201 preferentially inhibits Stat3 DNA-binding activity
over that of Stat1 (IC50 values, Stat3Stat3, 86 33M; Stat1Stat3,
160 43 M; and Stat1Stat1,300 M) and inhibits that of Stat5
with 1⁄2 the potency (IC50 value, 166 17 M). The appearance of
different degrees of activity of S3I-201 at 300 M is due to the fact
that different nuclear extract preparations were used, one from the
v-Src-transformed mouse fibroblasts (NIH 3T3/v-Src) containing
only activated Stat3 (Fig. 2A Left) and the other from the EGF-
stimulated NIH 3T3/hEGFR that contains activated Stat1, Stat3,
and Stat5 (Fig. 2A Right). Supershift analysis with anti-Stat3
antibody shows proteinhSIE complex (Fig. 2A Left, the last two
lanes) contains Stat3, whereas use of anti-Stat1 antibody or anti-
Stat5 antibody confirms that proteinMGFe complexes contain
Stat1 or Stat5, respectively (Fig. 2A Right, the last two lanes).
S3I-201 Disrupts Stat3Stat3 Complex Formation in Vitro and in Intact
Cells. To provide experimental data in support of S3I-201’s binding
to Stat3, we asked whether unphosphorylated, inactive Stat3 mono-
mer could interfere with the inhibitory effect of S3I-201 on active
Stat3 DNA-binding (inactive Stat3 monomer will interfere with the
inhibitory activity of S3I-201 if it interacts with the compound). To
answer this question, cell lysates of unphosphorylated, inactive
Stat3 monomer protein prepared from Sf-9 insect cells infected
with only baculovirus containing Stat3, as previously described (11,
12, 18, 19), and cell lysates of activated Stat3 dimer protein were
mixed together; the mixture was preincubated with S3I-201 for 30
min before incubation with the radiolabeled hSIE probe and EMSA
analysis carried out in the same manner as for Fig. 2A. The
unphosphorylated, inactive Stat3 monomer by itself had no signif-
icant effect on DNA-binding activity of activated Stat3 (Fig. 2B,
compare lane 2 to lane 1), because inactive Stat3 monomer is
incapable of binding DNA (19). By contrast, the presence of
inactive Stat3 monomer diminished the inhibitory effect of S3I-201
on the activated Stat3 in a dose-dependent manner, resulting in the
recovery of the active Stat3 DNA-binding activity (Fig. 2B, lanes
5–7 versus lanes 3 and 4). The Stat3 DNA-binding activity that was
otherwise inhibited (Fig. 2B, lanes 3 and 4) was partially or
completely restored in the presence of 4 or 5 l of inactive Stat3
lysates, respectively (Fig. 2B, lanes 6 and 7). These findings support
the S3I-201–Stat3 interaction and suggest the interaction is inde-
pendent of the activation status of Stat3. Similar studies were
performed by using independently prepared cell lysates from Sf-9
insect cells infected with only the baculovirus containing Stat1,
Stat5, or Src, as we have previously reported (11, 12, 18, 19). In
contrast to the effect observed with the inactive Stat3 monomer
(Fig. 2B, lanes 5–7), EMSA analysis showed that the presence of
inactive Stat1, Stat5, or Src lysate induces no significant recovery of
Stat3 DNA-binding activity (Fig. 2B, lanes 8–10, 11–13, and 14–16,
respectively). In the case of the Stat1 monomer lysate, minimal
recovery of Stat3 DNA-binding activity is observed (Fig. 2B, lane
10), which is evidence of a weak interaction of the Stat1 protein with
S3I-201, as revealed in the initial evaluation (Fig. 2A Right). The
amounts of proteins for each of Stat1, Stat3, or Stat5 monomer or
the Src lysate used in these studies was determined by SDS/PAGE
and Western blot analysis to be similar (Fig. 2B, lanes 17–20).
To further confirm the interaction of S3I-201 with Stat3 and to
demonstrate that it blocks Stat3Stat3 dimerization in intact cells,
Stat3 pull-down assays were performed. Viral Src transformed
(NIH 3T3/v-Src) mouse fibroblasts stably expressing Stat3-YFP
were transiently transfected with Flag-Stat3 (FLAG-ST3), treated
either with 0.05% DMSO (control) or with S31–201 for 24 h, and
then subjected to pull-down assay and SDS/PAGE. Western blot
analysis for FLAG of whole-cell lysates shows equal expression of
the FLAG-ST3 protein in the lysates in the transiently transfected
cells in both the control and S3I-201-treated cells (Fig. 2Cii).
Western blot analysis probing with anti-FLAG antibody of the
Stat3-YFP immunoprecipitates from control cells showed the pres-
ence of FLAG-ST3 protein (Fig. 2Ci Upper Left, lane 1), suggesting
Stat3-YFP and FLAG-ST3 proteins were pulled down together as
a complex. By contrast, Western blot analysis probing with anti-
FLAG antibody showed no detectable level of FLAG-ST3 protein
in the Stat3-YFP immunoprecipitates from S3I-201-treated cells
(Fig. 2Ci Upper Left, lane 2 vs. 1), suggesting the disruption by
S3I-201 of the complex formation between Stat3-YFP and FLAG-
ST3 proteins. The amounts of Stat3-YFP in the immunoprecipi-
tates are shown in Fig. 2Ci Lower Left. Similarly, Western blot
analysis probing with anti-YFP antibody of the FLAG-ST3 immu-
noprecipitates from control cells showed Stat3-YFP present in the
pulled-down lysate (Fig. 2Ci Lower Right, lane 3), but significantly
reduced in the FLAG-ST3 immunoprecipitates from the S3I-201-
Fig. 1. Application of computational modeling in in silico screening (virtual
screening) to identify the compound S3I-201 from a chemical database. (A)
S3I-201 (NSC 74859) docked to the SH2 domain of Stat3; a solvent-accessible
surfaceoftheprotein (renderedona6-Åshellof residues surroundingthe ligand)
is shown. It is color coded according to the electrostatic potential, with redmost
negative and dark blue most positive. Hydrogen bonding to Lys-591, Ser-611,
Ser-613, andArg-609 is shownbywhitedashed lines.CarbonatomsofS3I-201are
shown in green. (B) S3I-201 docked to the SH2 domain of Stat3 along with pTyr
peptide. Coloring for pTyr peptide is as follows: Ala, yellow; Pro, red; pTyr,
magenta; Leu, orange; and Lys, green.
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treated cells (Fig. 2Ci Lower Right, lane 4 vs. 3). The FLAG-ST3
protein amounts in the immunoprecipitates are shown (Fig. 2Ci
Upper Right).
S3I-201 Does Not Interfere with Lck-SH2 Domain–Phosphotyrosine
Interaction. To further investigate the selectivity of S3I-201 and to
rule out the possibility that it interacts with other SH2 domain-
containing proteins, we evaluated its effect on the binding between
the unrelated Src family protein, Lck, and the cognate phosphopep-
tide, EPQpYEEIEL. We used the in vitro ELISA study involving
the Lck-SH2-GST protein and the conjugate pTyr peptide, biotinyl-
-Ac-EPQpYEEIEL-OH (20), as described in Materials and Meth-
ods. Results from the ELISA show that the copresence of the
Lck-SH2-GST protein and its cognate pTyr peptide results in signal
induction (Fig. 2D, bar 4), suggesting an interaction between the
two (20). The addition of 30 M and 100 M S3I-201 has no effect
on the signal induction (Fig. 2D, compare bars 5 and 6 to bar 4),
indicating that S3I-201 does not interfere with the binding of the
Lck SH2 domain to its cognate pTyr peptide.
S3I-201 Inhibits Stat3 Activation in Intact Cells. To determine effect
of S3I-201 on intracellular Stat3 activation, NIH 3T3/v-Src mouse
fibroblasts and human breast cancer MDA-MB-231, MDA-MB-
435, and MDA-MB-468 cells, which harbor constitutively active
Stat3 (21–23), were treated with the compound and nuclear extracts
were prepared for Stat3 DNA-binding activity in vitro and EMSA
analysis. Compared with control (0.05% DMSO-treated cells, lane
1), S3I-201 induced a time-dependent inhibition of constitutive
Stat3 activation in NIH 3T3/v-Src fibroblasts (Fig. 2E, lanes 4–6).
By 24 h, constitutive Stat3 activation was significantly inhibited in
all three cell lines (Fig. 2E, lanes 4–6 and 8, 10, and 12). Further-
more, SDS/PAGE and Western blot analysis of whole-cell lysates
from NIH 3T3/v-Src fibroblasts show pTyr-705 Stat3 levels were
significantly diminished after 24-h treatment with S3I-201 (Fig. 2F),
whereas the total Stat3 protein level remained unchanged. This
inhibition of tyrosine phosphorylation may be explained by the fact
that, by binding to the Stat3 SH2 domain, S3I-201 prevents Stat3
from binding to the pTyr motifs of the receptor tyrosine kinases and
subsequently blocks de novo phosphorylation by tyrosine kinases.
By contrast, SDS/PAGE and Western blot analysis performed on
whole-cell lysates from mouse fibroblasts transformed by v-Src
(NIH 3T3/v-Src) or overexpressing the human EGFR (NIH 3T3/
hEGFR) and stimulated by EGF revealed that treatment with
S3I-201 for 24 h had no significant effect on the phosphorylation of
Shc (pShc), Erk1/2 (pErk1/2), or Src (pSrc) in cells (SI Fig. 7). Total
Erk1/2 protein levels were unchanged. Moreover, SDS/PAGE and
Western blot analysis with the anti-pTyr antibody 4G10 showed no
significant changes in the pTyr profile of NIH 3T3/v-Src fibroblasts
after 24-h treatment with S3I-201 (SI Fig. 7).
Selective Inhibition of Stat3 Transcriptional Activity by S3I-201. We
investigated S3I-201’s effect on Stat3-dependent transcriptional
activity. Normal mouse fibroblasts (NIH 3T3) were transiently
cotransfected with the Stat3-dependent luciferase reporter
pLucTKS3 and a plasmid encoding the v-Src oncoprotein that
activates Stat3, and cells were untreated (0.05% DMSO, control) or
treated with S3I-201. As previously reported (23), v-Src protein
mediated induction of the Stat3-dependent luciferase reporter
pLucTKS3 activity by 7-fold (Fig. 3 Left). This Stat3-dependent
pLucTKS3 induction was significantly inhibited by the treatment of
cells with S3I-201 in a dose-dependent manner (Fig. 3 Left). To
examine specificity of effects, normal mouse fibroblasts were co-
transfected with the Stat3-independent luciferase reporters pLuc-
SRE (23) or -casein promoter-driven Luc (24) together with v-Src
plasmid and treated with S3I-201 or without (0.05% DMSO). In
contrast to the effect on the induction of pLucTKS3 luciferase
reporter, v-Src-mediated induction of Stat3-independent pLucSRE
(23) or the -casein promoter-driven Luc (24) was not affected by
treatment with S3I-201 (Fig. 3 Center and Right).
S3I-201 Blocks Anchorage-Dependent and Independent Growth only in
Cells Where Stat3 is Persistently Activated. We next determined
whether this Stat3 activity inhibitor is able to inhibit the anchorage-
dependent and -independent (transformation) growth of human
and mouse cancer cell lines. The human breast carcinoma (MDA-
MB-231, MDA-MB-435, and MDA-MB-468) cell lines and the
v-Src-transformed mouse fibroblasts (NIH 3T3/v-Src), which har-
Fig. 2. Evaluation for effects of S3I-201 on STATs, Shc, Src, and Erks activation,
andonLck-SH2domainphosphopeptidebinding. (A)Nuclearextracts containing
activated STATproteinswerepreincubatedwithorwithout S3I-201 for 30min at
room temperature before incubationwith radiolabeled hSIE probe, which binds
Stat1 and Stat3, orMGFe probe, which binds Stat1 and Stat5, or nuclear extracts
were incubatedwith anti-Stat1, anti-Stat3, or anti-Stat5A antibody for 30min at
room temperature before incubation with radiolabeled probes, and were sub-
jected to EMSA analysis. (B) (i) Cell lysates containing activated Stat3 were pre-
incubated with S3I-201 or without (control, 0.05% DMSO) in the presence or
absence of increasing amount of cell lysates containing inactive Stat3 protein
(monomer), inactiveStat1protein (monomer), inactiveStat5protein (monomer),
or Src proteinbefore incubationwith radiolabeledhSIE probe followedbyEMSA
analysis. (ii) SDS/PAGE and Western blot analysis of cell lysate preparations of
equal amounts of total protein containing inactive Stat3 (monomer), Stat1
(monomer), or Stat5 (monomer), or Src protein and probed with anti-Stat3,
anti-Stat1, anti-Stat5, or anti-Src antibody. (C) (i) SDS/PAGE and Western blot
analysis of Stat3-yellow fluorescent protein (YFP) immunoprecipitates (i.p. YFP,
Left)probingforFLAG-Stat3(anti-FLAG,Upper)orStat3-YFP(anti-YFP,Lower),or
of FLAG-Stat3 immunoprecipitates (i.p. FLAG, Right) probing for Stat3-YFP (anti-
YFP, Lower) or FLAG-Stat3 (anti-FLAG, Upper); (ii) SDS/PAGE and Western blot
analysis of whole-cell lysates from FLAG-ST3-transiently transfected cells (input)
treatedwithS3I-201oruntreated(control)probingforFLAG. (D) InvitroELISAfor
the binding of Lck-SH2-GST to the conjugate biotinylated pTyr-peptide (EPQpY-
EEIEL), and effects of increasing concentration of S3I-201. Values are themean
SDof three independentdeterminations. (E) EMSAanalysisofStat3DNA-binding
activity innuclear extract preparations fromv-Src-transformedmousefibroblasts
(NIH 3T3/v-Src) treated for the indicated times or from the human breast cancer
MDA-MB-231,MDA-MB-435, andMDA-MB-468 cells treated for 48 hwith 100
M S3I-201 and incubated with radiolabeled hSIE probe. (F) SDS/PAGE and
Western blot analysis of whole-cell lysates from NIH 3T3/v-Src fibroblasts
untreated (control) or treated with S3I-201 (100 M, 24 h) probing with
anti-pTyr-705-Stat3 or anti-Stat3 antibody. Positions of STATDNA complexes
or proteins in gel are labeled; control lanes represent nuclear extracts treated
with 0.05% DMSO, and nuclear extracts or cell lysates prepared from 0.05%
DMSO-treated cells; asterisks (*) indicate supershifted complexes of
STATprobeantibody in the presence of anti-Stat1, anti-Stat3, or anti-Stat5
antibody.








bor constitutively active Stat3 and the human breast carcinoma
MDA-MB-453 cell line and normal mouse fibroblasts (NIH 3T3),
which do not harbor aberrant Stat3 activity, were treated with
S3I-201 and analyzed for viable cell number by trypan blue exclu-
sion and microscopy (Fig. 4A). S3I-201 significantly reduced viable
cell numbers and inhibited growth of transformed mouse fibro-
blasts NIH 3T3/v-Src and breast carcinoma cell lines (MDA-MB-
231, MDA-MB-435, and MDA-MB-468) (Fig. 4A). By contrast,
growth and viability of normal mouse fibroblasts (NIH 3T3) and the
breast carcinoma cell line (MDA-MB-453) without aberrant Stat3
activity were not significantly altered (Fig. 4A). Furthermore,
growth of v-Src-transformed mouse fibroblasts in soft-agar suspen-
sion is significantly inhibited by S3I-201 (Fig. 4B). By contrast,
soft-agar growth of the v-Ras-transformed counterpart (NIH 3T3/
v-Ras), which is independent of constitutively active Stat3, is
unaffected by treatment with S3I-201 (Fig. 4B).
S3I-201 Preferentially Induces Apoptosis of Malignant Cells Harboring
Constitutively Active Stat3. To determine whether the S3I-201
induced loss of tumor cell viability was due to apoptosis, the human
breast carcinoma cell lines MDA-MB-453 and MDA-MB-435 and
the normal mouse fibroblasts (NIH 3T3) and their v-Src-
transformed counterpart (NIH 3T3/v-Src) were untreated (0.05%
DMSO, control) or treated with S3I-201 for 48 h and analyzed by
annexin V binding and flow cytometry. At 30–100 M, S3I-201-
induced significant apoptosis in the representative human breast
carcinoma cell line MDA-MB-435 and NIH 3T3/v-Src, both of
which harbor constitutively active Stat3 (Fig. 5A). The breast
carcinoma MDA-MB-435 cell line is more sensitive to 30 M
S3I-201 (Fig. 5A). By contrast, the human breast cancer MDA-
MB-453 cells and the normal mouse fibroblasts (NIH 3T3), which
do not contain abnormal Stat3 activity, are less sensitive to S3I-201
at 100 M or less (Fig. 5A). At 300 M or higher, S3I-201 induced
general, nonspecific cytotoxicity independent of Stat3 activation
status.
We reasoned that if the ability of S3I-201 to induce tumor cell
apoptosis is due to its ability to inhibit Stat3 activation, then the
constitutively dimerized and persistently activated Stat3C (25)
should rescue cells from S3I-201-induced apoptosis. To this end, the
breast carcinoma MDA-MB-231 cells, which harbor activated
Stat3, were transiently transfected with Stat3C and evaluated for
apoptosis. Consistent with results in Fig. 5A, S3I-201 induced
50–80% apoptosis in untransfected or mock-transfected human
breast carcinoma MDA-MB-231 cells (Fig. 5B Left). By contrast,
cells transfected with Stat3C and treated with S3I-201 showed
greatly diminished apoptosis (Fig. 5BLeft),2-fold compared with
9- or 5-fold apoptosis in nontransfected or mock-transfected cells,
respectively. There is an increase in the background level of cell
death, which could be due to the effects of transfection.
To establish that the effect of S3I-201 is due to its interaction with
the Stat3 SH2 domain, similar studies were performed in cells that
were transiently transfected with an expression vector for either the
N-terminal region of Stat3 (ST3-NT) or the Stat3 SH2 domain
(ST3-SH2) and treated with or without S3I-201. Annexin V binding
and flow cytometry showed that although mock-transfected cells
were strongly induced by S3I-201 to undergo apoptosis (Fig. 5B
Right), similar to the Stat3C-transfected cells, the overexpression of
the Stat3-SH2 domain diminished the apoptotic effects of S3I-201
(Fig. 5B Right). In contrast, ST3-NT has no effect on the ability of
S3I-201 to induce apoptosis of malignant cells (Fig. 5B Right).
S3I-201 Represses the Expression of the Stat3-Regulated Genes En-
coding Cyclin D1, Bcl-xL, and Survivin. To investigate the molecular
mechanisms for the cell growth inhibition and apoptosis by S3I-201,
we examined the expression of the known Stat3 target genes in the
v-Src-transformed mouse fibroblasts (NIH 3T3/v-Src) and the
human breast carcinoma MDA-MB-231 cell line, which harbor
constitutively active Stat3. Immunoblot analysis of whole-cell ly-
sates showed significant reduction in expression of the cyclin D1,
Bcl-xL, and survivin proteins in response to S3I-201 treatment (Fig.
5C), indicating that S3I-201 represses induction of the cell cycle and
anti-apoptotic regulatory genes in malignant cells.
S3I-201 Induces Regression of Human Breast Tumor Xenografts. We
extended these studies to evaluate the antitumor efficacy of S3I-201
in mouse models with human breast tumor xenografts that harbor
constitutively active Stat3. Human breast (MDA-MB-231) tumor-
bearing mice were given an i.v. injection of S3I-201 or vehicle every
2 or every 3 days for 2 weeks, and tumor measurements were taken
every 2–3 days. Compared with control (vehicle-treated) tumors,
Fig. 3. S3I-201 suppresses Stat3-dependent but not Stat3-independent tran-
scriptional activity. Shown are luciferase reporter activities in cytosolic extracts
preparedfromnormalmousefibroblasts (NIH3T3) transiently cotransfectedwith
the Stat3-dependent (pLucTKS3), or the Stat3-independent (pLucSRE or -casein
promoter-drivenLuc) luciferase reporters togetherwithaplasmidexpressing the
v-Srconcoprotein thatactivates all three reporters, anduntreated (0.05%DMSO,
control) or treated with 100 M S3I-201 for 24 h. Values are the mean SD of
three independent determinations.
Fig. 4. S3I-201 inhibits anchorage-dependent and -independent growth only
of cells that contain persistently active Stat3. (A) Normal mouse fibroblasts (NIH
3T3) and v-Src transformed counterparts (NIH 3T3/v-Src), as well as the human
breast carcinoma cells (MDA-MB-453,MDA-MB-435,MDA-MB-231, orMDA-MB-
468)were untreated (0.05%DMSO, control) or treatedwith 100MS3I-201 and
countedby trypanblue exclusiononeachof 4days for viable cell number. Values
are the mean SD of three independent determinations. (B) v-Src-transformed
mouse fibroblasts (NIH 3T3/v-Src) and their v-Ras-transformed counterparts (NIH
3T3/v-Ras) were grown in soft-agar suspension and untreated (0.05% DMSO,
control) or treated with 100 M S3I-201 every 3 days until large colonies were
visible, which were enumerated. Values are the mean SD of three or four
independent determinations.
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which continued to grow, human breast tumors in mice that
received S3I-201 displayed strong growth inhibition (Fig. 6A).
Continued evaluation of treated mice on termination of treatment
showed no resumption of tumor growth (data not shown), suggest-
ing potentially a long-lasting effect of S3I-201 on tumor growth. To
determine that target was inhibited by S3I-201, lysates were pre-
pared from tumor tissue from one control animal and from the
residual tumor tissue in two treated-mice for Stat3 DNA-binding
activity in vitro, as we have previously done (18). EMSA analysis
showed strong inhibition of Stat3 DNA-binding activity in residual
tumor tissue from mice treated with S3I-201 (T1 and T2) compared
with control tumor (Fig. 6B, lanes 1–3). See SI Results for SDS/
PAGE and Western blot analysis of lysates. Moreover, EMSA
analysis of in vitro Stat3 DNA-binding activity also showed that
preincubation of lysates of equal total protein from control tumor
tissue with 10, 30, and 100 M S3I-201 before incubation with
radiolabeled hSIE probe resulted in a dose-dependent abrogation
of Stat3 activity (Fig. 6B, lanes 4–6), as observed originally in Fig.
2A Left. Together these studies establish the proof-of-concept for
the antitumor effect of S3I-201 in tumors that harbor constitutively
active Stat3.
Discussion
The present study demonstrates the feasibility of using x-ray crys-
tallographic data and computational modeling as a basis for a
structure-based virtual screening to identify chemical probes and
small-molecule binders of the Stat3 SH2 domain. Similar compu-
tational analysis has been applied in the development of inhibitors
of Stat3 and other proteins (14, 15). The docking pose of S3I-201
suggests that its aminosalicylic moiety mimics the phenylphosphate
group of the PpYLKT motif. Furthermore, its carboxyl group is
hydrogen bonded to Arg-609, Ser-611, and Ser-613 of Stat3, while
the phenolic hydroxyl group is hydrogen-bonded to Lys-591. More-
over, the proximity of the Lys-591 to the benzene ring with the
phenolic hydroxyl group suggests the possibility of a stabilizing
-electron–cation interaction. Also, the tolyl group is buried within
a partially hydrophobic pocket, which contains the tetramethylene
portion of the side chain of Lys-592 and the trimethylene portion
of the side chain of Arg-595, along with residues Ile-597 and Ile-634.
We believe that these features (the phosphate mimic and hydro-
phobic side chain) combine and explain how S3I-201 binds to the
SH2 domain of Stat3.
The native pTyr peptide inhibitor of Stat3, PpYLKTK, was
previously shown to disrupt Stat3Stat3 dimerization, thereby in-
ducing antitumor cell effects (12). In pull-down assays, we demon-
strated that S3I-201 disrupts the complex formation between two
Stat3 monomers. S3I-201 preferentially interacts with Stat3 mono-
mer protein over Stat1 or the Src family protein and has 1⁄2 the
affinity for Stat5. In cells, the interactions with Stat3 will prevent de
novo phosphorylation and activation of Stat3 monomer. Thus,
S3I-201 mediates selective inhibition of Stat3 transcriptional activ-
ity and induces cell growth inhibition, loss of viability, and apoptosis
of malignant cells that harbor constitutively active Stat3, as well as
blocks v-Src transformation, events that are all consistent with the
abrogation of Stat3 activation (11, 12, 22, 26, 27). The observation
that overexpressed exogenous Stat3 SH2 domain, but not Stat3 N
terminus in malignant cells, protects against S3I-201-induced apo-
ptosis strongly supports the Stat3 SH2 domain as the target of
S3I-201. Our findings further suggest the antitumor cell effects of
S3I-201 are mediated by suppressing aberrant Stat3-induced dys-
regulation of the cell-cycle control and the anti-apoptotic genes.
Furthermore, in vivo antitumor effects of S3I-201 in human breast
tumor xenografts establish the proof-of-concept for the therapeutic
potential of S3I-201 as a Stat3 inhibitor in human tumors that
harbor constitutively active Stat3.
Here, we report a Stat3 SH2 domain binder and an inhibitor of
Stat3 signaling, which is structurally different from previously
identified dimerization disrupters, peptides and peptidomimetics
(11, 12), or other Stat3 inhibitors, such as the G-quartet oligonu-
cleotides (28), peptide aptamers (29), platinum (IV) complexes (18,
Fig. 5. S3I-201 inhibits cyclin D1,
Bcl-xL, and survivin expression and
induces apoptosis in a Stat3-depen-
dent manner. (A) Normal NIH 3T3
mouse fibroblasts and their v-Src-
transformed counterparts (NIH 3T3/
v-Src) and the human breast carci-
noma MDA-MB-453 and MDA-MB-
435 cell lines were untreated (0.05%
DMSO) or treated with 30–300 M
S3I-201 for 48 h and subjected to an-
nexin V staining and flow cytometry. 7AAD, 7-aminoactinomycin D. (B) Human breast carcinomaMDA-MB-231 cells were transfected with pcDNA3 (Mock) or Stat3C
orwereuntransfected (Non) (Left), or the v-Src-transformedmousefibroblasts (NIH 3T3/v-Src)were transfectedwith pcDNA3 (Mock), theN terminus of Stat3 (ST3-NT),
or the Stat3 SH2 domain (ST3-SH2) for 4 h (Right). Twenty-four hours after transfection, cells were untreated [0.05% DMSO ()] or treated () with 100 M S3I-201
for anadditional 24hand subjected to annexinV stainingandflowcytometry. ForAandB, values are themean SDof six independentdeterminations. (C) SDS/PAGE
andWestern blot analysis of whole-cell lysates prepared from the v-Src-transformedmouse fibroblasts (NIH 3T3/v-Src) or the human breast cancer MDA-MB-231 cells
untreated (DMSO, control) or treated with 100 M S3I-201 for 48 h. Probing was with anti-cyclin D1, anti-Bcl-xL, and anti-survivin antibodies. Western blot data are
representative of three independent analyses.
Fig. 6. Tumor growth inhibition by S3I-201. (A) Human
breast (MDA-MB-231) tumor-bearing mice were given
S3I-201 (5mg/kg) i.v. every 2 or every 3 days. Tumor sizes
weremonitored every 2–3 days, converted to tumor vol-
umes, and plotted. Values are the mean SD of eight
tumor-bearing mice each. (B) Three days after the last
S3I-201 injection, animals were killed, tumors from one
control animal (DMSO-treated) or residual tumor tissue
from two S3I-201-treated (T1 and T2) mice were ex-
tracted,and lysatepreparationswithequal totalproteins
were analyzed for Stat3 activation by incubating with
radiolabeled hSIE probe and subjecting the products to
EMSA analysis (lanes 1–3), or lysates from control tumor tissue of equal total proteins were preincubatedwith or without increasing concentrations of S3I-201 before
incubation with radiolabeled hSIE probe and subjecting the products to EMSA analysis (lanes 1, 4, 5, and 6). Positions of Stat3DNA complexes are shown.








19), cucurbitacin (30), and STA-21 (NSC 628869) (15). Although
SH2 domains have been noted to have a high sequence similarity
in their 100 amino acids (31, 32), S3I-201 has preference for Stat3
in that at concentrations that inhibit Stat3, S3I-201 has a low effect
on Stat1 and Stat5, no interaction with the Src family proteins, weak
inhibition of Erk1/2 and Shc activation, and low toxicity to cells with
no aberrant Stat3. Our study supports computational modeling
application in structure-based virtual screening for identifying Stat3
inhibitors from chemical libraries, and together with another report
(15) is among the first to identify Stat3 inhibitors by this approach.
Materials and Methods
Cells and Reagents. Normal mouse fibroblasts (NIH 3T3) and their
counterparts transformed by v-Src (NIH 3T3/v-Src), v-Ras (NIH
3T3/v-Ras), or overexpressing the human EGFR (NIH 3T3/
hEGFR), and the human breast cancer (MDA-MB-231, MDA-
MB-435, MDA-MB-453, and MDA-MB-468) cells have all been
previously reported (11, 21, 22, 33). Cells were grown in DMEM
containing 10% FBS. Antibodies C-136 and E23X for Stat1, C20
and C20X for Stat3, and L-20 and L-20X for Stat5A were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA), and polyclonal
anti-Src and anti-phosphoSrc antibodies were from Cell Signaling
Technology (Danvers, MA).
Transient Transfection of Cells and Treatment with Compound.
Twelve to 24 h after seeding, cells were transfected with the
appropriate plasmids. For detailed procedure information, see SI
Materials and Methods. Twenty-four hours after transfection, cells
were untreated (0.05% DMSO) or treated with S3I-201 (100 M)
for an additional 24 h and harvested, and cytosolic extracts were
prepared for luciferase assay, as described (11, 23), or cells were
analyzed by annexin V binding and flow cytometry.
Cytosolic Extracts and Cell Lysate Preparation, Luciferase and -Ga-
lactosidase Assay. Cytosolic extract preparation from mammalian
cells for luciferase (Promega, Madison, WI) and -galactosidase
assays, and from recombinant baculovirus-infected Sf-9 cells to
obtain Stat1, Stat3, and Stat5 monomers, and Src proteins are as
described previously (11, 23, 34).
Nuclear Extract Preparation, EMSAs, and Densitometric Analysis.
Nuclear extract preparations and EMSAs were carried out as
previously described (21–23). The 32P-labeled oligonucleotide
probes used were hSIE that binds Stat1 and Stat3 (22, 35) and
MGFe for Stat1 and Stat5 binding (36, 37). Except where indicated,
nuclear extracts were preincubated with compound for 30 min at
room temperature before incubation with the radiolabeled probe.
Bands corresponding to DNA-binding activities were scanned and
quantified for each concentration of compound and plotted as a
percentage of control (vehicle) against concentration of compound;
the IC50 values were derived from these plots, as previously
reported (11, 19).
Immunoprecipitation (IP) and Western Blotting. Whole-cell lysates
and tumor tissue lysates from pulverized tumor tissue were pre-
pared in boiling SDS sample loading buffer to extract total proteins,
as previously described (12, 18, 19, 22). For detailed procedure
information and IP, see SI Materials and Methods.
Lck-SH2 Domain–Phosphopeptide-Binding Assay. In vitro ELISA
study involving the Lck-SH2-GST protein and the conjugate pTyr
peptide, biotinyl--Ac-EPQpYEEIEL-OH (Bachem Biosciences,
King of Prussia, PA) was performed as previously described (20).
For detailed procedure information, see SI Materials and Methods.
Soft-Agar Colony-Formation Assay. Colony formation assays were
carried out in six-well dishes, as described previously (11). Treat-
ment with S3I-201 was initiated 1 day after seeding cells by adding
100 l of medium with or without S3I-201 and repeating every 3
days, until large colonies were evident.
Measurement of Apoptosis by Flow Cytometry. Proliferating cells
were treated with or without S3I-201 for up to 48 h. In some cases,
cells were first transfected with Stat3C, ST3-NT, or ST3-SH2
domain or mock-transfected for 24 h before treatment with com-
pound for an additional 24–48 h. Cells were then detached and
analyzed by annexin V binding (BD Biosciences, San Diego, CA)
according to the manufacturer’s protocol and flow cytometry to
quantify the percent apoptosis.
Mice and in Vivo Tumor Studies. Six-week-old female athymic nude
mice were purchased from Harlan (Indianapolis, IN) and main-
tained in the institutional animal facilities approved by the Amer-
ican Association for Accreditation of Laboratory Animal Care.
Athymic nude mice were injected in the left flank area s.c. with 5
106 human breast cancer MDA-MB-231 cells in 100 l of PBS.
After 5–10 days, tumors with a diameter of 3 mm were established.
Animals were given S3I-201 i.v. at 5 mg/kg every 2 or 3 days for 2
weeks and monitored every 2 or 3 days. Animals were stratified so
that the mean tumor sizes in all treatment were nearly identical.
Tumor volume was calculated according to the formula V 0.52
a2 b, where a is the smallest superficial diameter and b is the
largest superficial diameter.
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